Skip to main content
Caplight Logo









Elucid

Elucid

Private
Boston, MassachusettsHealthcare & Life Scienceshttps://elucid.com/

Last Round

Series D

Sep 2, 2026

Total Funding Raised

$170.75M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Elucid is a medical technology company that develops AI-powered imaging software to quantify and characterize atherosclerotic plaque for personalized cardiovascular disease treatment.

Sector

Healthcare & Life Sciences

Verticals

Medical Imaging, Medical AI, Healthcare Analytics, Medical Devices

Business Model

B2B

Customer Profile

Usage-Based SaaS, Services & Consulting

AI Layer

Application

Keywords

medical imaging AIcardiovascular imagingarterial plaque analysisplaque quantificationcoronary plaque analysiscardiac CT analysisAI-powered diagnosticscardiology softwarenon-invasive diagnosticsCPT 75577clinical decision supportmedtechcardio AIvascular imagingusage-based SaaS

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Elucid Comparables

Compare Elucid with similar companies based on industry and business-model similarity.

Elucid comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Cleerly
93%
HeartFlow
87%
Circle Cardiovascular Imaging
84%

Elucid Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series DSep 2, 2026
Series CNov 9, 2023
Series BJun 22, 2022
Series AMay 10, 2021
GrantSep 1, 2015

Elucid Investors

Notable investors and investment history

Elucid investors
InvestorRounds
Bold BrainSeries B
IAG Capital PartnersSeries B, Series A, Series D
MedTex VenturesSeries B, Series C, Series A
NIH RADxGrant
BiovergeSeries B
Willamette Valley CapitalSeries A
Checkmate CapitalSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Sep 2, 2026

    $55M round with IAG Capital Partners and Elevage Medical Technologies.

  • Apr 15, 2026

    Commercial availability of the Lesion Inspection Tool for plaque analysis.

Elucid Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Elucid Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Elucid's valuation, stock price, and market status.

Firmographic Details

HeadquartersBoston, Massachusetts
Employee Range143
Year Founded2013
Last FundingSep 2, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?